GLP-1 maintenance phase: what the science says about staying off

What did @loseitwithannie actually say?

Annie documented her 139th week on a GLP-1 medication, which she identifies as tirzepatide ("Terz"). She mentions being in a maintenance phase, reports losing "75 poundcakes" total, and admits she regularly forgets her injection schedule. She also notes she takes "the amount that has been prescribed" and does pre-injection prep including hitting her protein intake. No wild claims, no miracle promises. Just a long-term user going through her routine.

The video is refreshingly low on hype. She is not selling anything, not claiming tirzepatide cured a disease, and not recommending a specific dose to her audience. What she is doing is normalizing long-term GLP-1 use for weight maintenance, which is worth examining on its own terms.

Does the science back this up?

Yes, largely. Long-term tirzepatide use for weight management is supported by clinical data, and the maintenance framing she uses aligns with how trials actually structure extended treatment. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed that patients who continued tirzepatide after an initial weight loss period maintained significantly more weight loss than those who switched to placebo. Discontinuing the drug led to weight regain averaging about 14% body weight within a year.

Her 75-pound loss over roughly 2.5 years is plausible. SURMOUNT-1 (Jastreboff et al., 2022, NEJM) reported mean weight loss of up to 22.5% of body weight with the highest tirzepatide dose over 72 weeks. A 75-pound loss for someone with a higher starting weight fits squarely within that range, possibly even at a moderate dose over a longer timeline.

The protein prep she mentions is also grounded in evidence. Research consistently shows higher protein intake helps preserve lean muscle mass during GLP-1-induced weight loss (Biolo et al., 1997, American Journal of Physiology, and more recently supported by Wycherley et al., 2012, American Journal of Clinical Nutrition).

What did they get wrong (or right)?

She got more right than wrong here. The maintenance framing is accurate. GLP-1 medications are not a short-term fix, and the data backs that up. Calling it a managed, ongoing treatment rather than a diet is clinically appropriate.

The one thing worth flagging is not a factual error but a practical gap. Forgetting injection timing on a weekly medication like tirzepatide is more consequential than she lets on. While she jokes about it, dosing consistency matters. Missing or significantly delaying doses can reduce efficacy and, depending on how late the injection is, may require restarting protocols per prescribing guidelines. The FDA prescribing information for Zepbound notes that if a dose is missed by more than four days, the patient should skip that dose and resume on the next scheduled day. That is not a minor detail to wave off with "I'm human."

She is not giving bad advice. She is just underselling a real adherence issue that affects outcomes, and her 69,000 viewers may take away that forgetting is fine when it is actually something worth managing better.

What should you actually know?

Long-term GLP-1 use is the direction the clinical evidence points toward for sustained weight management. This is not a controversial position anymore. The American Diabetes Association and Obesity Society both acknowledge that obesity is a chronic condition requiring long-term treatment, not a short course of medication followed by lifestyle alone.

Tirzepatide specifically is a dual GIP and GLP-1 receptor agonist, which distinguishes it pharmacologically from semaglutide. It is not just a stronger version of Ozempic. The mechanism is different, and the weight loss outcomes in trials have generally been larger. Do not conflate them.

If you are on a weekly injectable GLP-1 and struggling with adherence, there are legitimate tools including app reminders, pairing injections with a weekly anchor event, and pharmacist counseling. Annie is right that it is a real problem. The solution is not just accepting it as inevitable.

One more thing: that brief nausea she mentions at the end is common immediately post-injection for some users and typically resolves quickly. It is not a red flag on its own, but persistent or worsening nausea warrants a conversation with a prescriber, not just powering through.